Abstract
The most precise word that can be used to describe menopause is change. The most dramatic alteration in body function for older women is the cessation of menses, the usual monthly flow of bloody vaginal fluid. This obviously easily perceived and recognized phenomenon announces a new era for aging women; a new life passage with a loss of fertility and a growing awareness with new symptoms of the inexorable process of aging. This chapter will focus upon the impact of this part of the woman’s life cycle upon the vagina and the vulva.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Society for Reproductive Medicine. Age and Fertility: A Guide for Patients (Patient Information Series). Birmingham: American Society for Reproductive Medicine, 2003.
Hillier SL, Lau RJ. Vaginal microflora in post-menopausal women who have not received estrogen replacement therapy. Clin Infect Dis. 1997;25(Suppl 2):S123–126.
Pabich WL, Fihn SD, Stamm WE, et al. Prevalence and determinants of vaginal flora alternations in post-menopausal women. J Infect Dis. 2003;188:1054–1058.
Raz R, Stamm WE. A controlled trial of intravaginal estriol in post-menopausal women with recurrent urinary tract infection. N Engl J Med. 1993;329:753–756.
Sobel JD. Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol. 1994;171:1215–1220.
Farage M, Singh M, Ledger WJ. Investigation of the sensitivity of a cross-polarized light visualization system to detect subclinical erythema and dryness in women with vulvovagintis. Am J Obstet Gynecol. 2009;201:1e1–1e6.
Pfeilschifter J, Kodtiz R, Pfohl M, et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23:90–119.
Hancock REW. Lationic peptides: effectors in innate immunity and novel antimocrobials. Lancet Infect Dis. 2001;1:156–164.
Addison WA, Livengood CH III, Hill GB, et al. Necrotizing fasciitis of vulvar origin in diabetes patients. Obstet Gynecol. 1984;63:473–479.
Rossouw TE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomize controlled trial. JAMA. 2002;288:321–333.
Hulley S, Grady B, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. JAMA. 1998;280:605–613.
Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465–1477.
Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in post-menopausal women. N Engl J Med. 2009;360:573–582.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this entry
Cite this entry
Ledger, W.J. (2010). Aging Genital Skin and Hormone Replacement Therapy Benefits. In: Farage, M.A., Miller, K.W., Maibach, H.I. (eds) Textbook of Aging Skin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-89656-2_26
Download citation
DOI: https://doi.org/10.1007/978-3-540-89656-2_26
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-89655-5
Online ISBN: 978-3-540-89656-2
eBook Packages: MedicineReference Module Medicine